The Indole–AhR–Treg axis as a microbiome-encoded immune checkpoint in type 1 diabetes
Abstract
Type 1 diabetes (T1D) is an autoimmune disease driven by the progressive destruction of pancreatic β-cells following failure of peripheral immune tolerance. Increasing evidence identifies the gut microbiome as a critical upstream regulator of this process through its control of microbiota-derived immunoregulatory metabolites. Among these, tryptophan-derived indole metabolites have emerged as central modulators of the aryl hydrocarbon receptor (AhR)–regulatory T cell (Treg) axis, a key checkpoint governing mucosal and systemic immune homeostasis. In individuals at risk for T1D, gut dysbiosis has been associated with altered commensal composition and tryptophan metabolism that may reduce the availability of selected AhR-active indole metabolites, including indole-3-acetic acid (IAA), indole-3-carboxaldehyde (ICA), and indole-3-propionic acid (IPA). These metabolites regulate Treg differentiation, macrophage polarization, epithelial barrier integrity, and effector T cell activation through context-dependent AhR- and PPAR-mediated signaling pathways. Disruption of this axis promotes inflammatory Th1/Th17 responses, intestinal barrier dysfunction, and progression of islet autoimmunity. A central concept emerging from recent studies is that the immunological outcome of AhR activation depends not only on ligand identity, but also on delivery compartment, concentration, cellular target, and inflammatory context — a framework we term the “Indole Paradox.” This paradigm helps reconcile why some AhR-targeting interventions exacerbate autoimmunity whereas others restore immune tolerance. In this review, we synthesize current mechanistic and translational evidence linking microbiome-derived indole signaling to T1D pathogenesis and evaluate emerging therapeutic strategies targeting this axis, including dietary modulation, postbiotic metabolites, pharmacological AhR agonists, fecal microbiota transplantation, and engineered bacterial therapeutics. We propose that context-directed modulation of the indole–AhR–Treg axis represents a promising next-generation strategy for restoring immune tolerance and preventing autoimmune progression in T1D.
Related
- Immune checkpoint inhibitors and the inflammatory dysregulation: decoding cutaneous and gastrointestinal immune-related adverse events for the allergist and immunologist
- Patient-Derived Melanoma Organoids Preserve Tumor-Immune Heterogeneity and Reveal Context-Dependent Responses to Immune Checkpoint Blockade
- Commentary: Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical management
- mtDNA Activates AIM2-Mediated PANoptosis in Interstitial Macrophages to Promote Immune Checkpoint Inhibitor Pneumonitis
- A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets
BibTeX
@article{delgado2026indoleahrtreg,
title = {{The Indole–AhR–Treg axis as a microbiome-encoded immune checkpoint in type 1 diabetes}},
author = {Kaylee Delgado and Alexia Espitia and Kate PopeJoy and Lila Mace and Michelle Lew and Benny Shone Song and Rakesh Kumar and Jianxun Song},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1949305},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1949305},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The Indole–AhR–Treg axis as a microbiome-encoded immune checkpoint in type 1 diabetes
AU - Kaylee Delgado
AU - Alexia Espitia
AU - Kate PopeJoy
AU - Lila Mace
AU - Michelle Lew
AU - Benny Shone Song
AU - Rakesh Kumar
AU - Jianxun Song
PY - 2026
DA - 2026/10/30
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1949305
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1949305
AB - Type 1 diabetes (T1D) is an autoimmune disease driven by the progressive destruction of pancreatic β-cells following failure of peripheral immune tolerance. Increasing evidence identifies the gut microbiome as a critical upstream regulator of this process through its control of microbiota-derived immunoregulatory metabolites. Among these, tryptophan-derived indole metabolites have emerged as central modulators of the aryl hydrocarbon receptor (AhR)–regulatory T cell (Treg) axis, a key checkpoint governing mucosal and systemic immune homeostasis. In individuals at risk for T1D, gut dysbiosis has been associated with altered commensal composition and tryptophan metabolism that may reduce the availability of selected AhR-active indole metabolites, including indole-3-acetic acid (IAA), indole-3-carboxaldehyde (ICA), and indole-3-propionic acid (IPA). These metabolites regulate Treg differentiation, macrophage polarization, epithelial barrier integrity, and effector T cell activation through context-dependent AhR- and PPAR-mediated signaling pathways. Disruption of this axis promotes inflammatory Th1/Th17 responses, intestinal barrier dysfunction, and progression of islet autoimmunity. A central concept emerging from recent studies is that the immunological outcome of AhR activation depends not only on ligand identity, but also on delivery compartment, concentration, cellular target, and inflammatory context — a framework we term the “Indole Paradox.” This paradigm helps reconcile why some AhR-targeting interventions exacerbate autoimmunity whereas others restore immune tolerance. In this review, we synthesize current mechanistic and translational evidence linking microbiome-derived indole signaling to T1D pathogenesis and evaluate emerging therapeutic strategies targeting this axis, including dietary modulation, postbiotic metabolites, pharmacological AhR agonists, fecal microbiota transplantation, and engineered bacterial therapeutics. We propose that context-directed modulation of the indole–AhR–Treg axis represents a promising next-generation strategy for restoring immune tolerance and preventing autoimmune progression in T1D.
SN - 1664-3224
ER -